Work

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Year: 2008

Type: article

Source: Oncogene

DOI: 10.1038/onc.2008.109

Authors: D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, L R Chirieac, R F Padera, G I Shapiro, A Baum, F Himmelsbach, W J Rettig, M Meyerson, F Solca, H Greulich, K-K Wong

Institutions: Dana-Farber Cancer Institute, Broad Institute, Brigham and Women's Hospital, Harvard University, Beth Israel Deaconess Medical Center, Boehringer Ingelheim (Austria), Boehringer Ingelheim (Germany)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Institute on Aging, National Cancer Institute

Awards: G1437721334, G1514577054, G249069283, G3167708942, G458608165, SPORE in Lung Cancer, G7630262769, G7816045031, Cyclin-Dependent Kinase Inhibition During S Phase

OpenAlex ID: W2063391304

FWCI: 35.03

Cites: 37

Cited by: 1,434

Related to: 10